Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Core Insights - Mainz Biomed N.V. announced significant findings from the ColoFuture and eAArly DETECT studies, demonstrating a sensitivity of 92.3% for colorectal cancer and 82.3% for advanced precancerous lesions [1][2] - The studies involved a total of 690 subjects across 30 clinical sites, making it the largest dataset to date for this type of analysis [2] - The company will present its findings at the ASCO 2024 Annual Meeting, highlighting a novel, non-invasive multimodal screening test that integrates mRNA biomarkers and an AI algorithm [3] Company Overview - Mainz Biomed specializes in molecular genetics diagnostics, focusing on early cancer detection, with its flagship product being ColoAlert®, a non-invasive test for colorectal cancer [6] - The company is preparing for a pivotal FDA clinical study to gain regulatory approval for its products in the U.S. market [6] - Mainz Biomed's product portfolio also includes PancAlert, an early-stage pancreatic cancer screening test [6] Industry Context - Colorectal cancer is the third most common cancer globally, with over 1.9 million new cases reported in 2020 [5] - The U.S. Preventive Services Task Force recommends stool DNA tests for colorectal cancer screening every three years starting at age 45, indicating a significant market opportunity [5] - Approximately one-third of U.S. residents aged 50-75 have never been screened for colon cancer, representing a market opportunity exceeding $4.0 billion [5]